Evidence map›Paper›PMID 34202704›Full record

ArticleInternational journal of molecular sciences2021

New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration.

Justyna Jakubowska, Bartłomiej Pawlik, Krystyna Wyka, Małgorzata Stolarska, Katarzyna Kotulska, Sergiusz Jóźwiak, Wojciech Młynarski, Joanna Trelińska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Justyna JakubowskaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.
Bartłomiej PawlikDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0002-8803-1033
Krystyna WykaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.
Małgorzata StolarskaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.
Katarzyna KotulskaDepartment of Neurology & Epileptology and Pediatric Rehabilitation, The Children's Memorial Health Institute, ul. Dzieci Polskich 20, 00-999 Warsaw, Poland.
Sergiusz JóźwiakDepartment of Child Neurology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warsaw, Poland.ORCID 0000-0003-3350-6326
Wojciech MłynarskiDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0003-2714-5851
Joanna TrelińskaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, ul. Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0003-1484-4274
Medical University of Lodz · PLMedical University of Warsaw · PLChildren's Memorial Health Institute · PL

Funding

Narodowe Centrum Nauki 2015/19/B/NZ5/02229Uniwersytet Medyczny w Lodzi 503/1-090-04/503-11-001-19Uniwersytet Medyczny w Lodzi 503/1-090-04/503-11-003
6 · The paper itself

Abstract

The aim of this study was to evaluate the effect of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, on red blood cell parameters in the context of iron homeostasis in patients with tuberous sclerosis complex (TSC) and evaluate its effect on cell size in vitro. Everolimus has a significant impact on red blood cell parameters in patients with TSC. The most common alteration was microcytosis. The mean MCV value decreased by 9.2%, 12%, and 11.8% after 3, 6, and 12 months of everolimus treatment. The iron level declined during the first 3 months, and human soluble transferrin receptor concentration increased during 6 months of therapy. The size of K562 cells decreased when cultured in the presence of 5 μM everolimus by approximately 8%. The addition of hemin to the cell culture with 5 μM everolimus did not prevent any decrease in cell size. The stage of erythroid maturation did not affect the response to everolimus. Our results showed that the mTOR inhibitor everolimus caused red blood cell microcytosis in vivo and in vitro. This effect is not clearly related to a deficit of iron and erythroid maturation. This observation confirms that mTOR signaling plays a complex role in the control of cell size.

Indexed as

AdolescentBiomarkersCell DifferentiationCell LineCell SizeChildChild, PreschoolErythrocyte IndicesErythrocytesEverolimusFlow CytometryHumansIronK562 CellsProtein Kinase InhibitorsTOR Serine-Threonine KinasesBiomarkersEverolimusIronMTOR protein, humanProtein Kinase InhibitorsTOR Serine-Threonine KinaseseverolimusK562 cellsmicrocytosis of the red blood cellsmTOR inhibitor

Identifiers

PMID34202704
PMCPMC8268656
OpenAlexW3174054889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.